A prospective,multicenter, randomized, parallel-group,open-label study of aripiprazole in the management of patients with schizophrenia

A prospective,multicenter, randomized, parallel-group,open-label study of aripiprazole in the management of patients with schizophrenia - Chiba Broad Effectiveness Trial With Aripiprazole (Chiba-BETA)

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000001650

Enrollment

300

Registered

2009-01-22

Start date

2009-01-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Interventions

Aripiprazole Standard control

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: With a diagnosis of schizophrenia and noticed as schizophrenia. Outpatients. Taking a certain antipsychotic four weeks long. A switch from current antipsychotic medicine was judged clinically reasonable.

Exclusion criteria

Exclusion criteria: Pregnant or breastfeeding women. Not noticed as schizophrenia. With diabetes.

Design outcomes

Primary

Measure	Time frame
Preference of Medicine(POM)	—

Countries

Japan

Contacts

Public ContactTomihisa Niitsu

Graduate School of Medicine, Chiba University Department of Psychiatry

niitsu@chiba-u.jp043-226-2148

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026